Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AqueSys, Inc.
With
Allergan
A prospective, multi-center, single arm, open-label clinical trial to evaluate the safety and IOP lowering performance of the AqueSys XEN 45 Glaucoma Implant in refractory glaucoma patients.
Age
45–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of Refractory Glaucoma
Maximally-tolerated medicated IOP at two preoperative visits of ≥20 mmHg and ≤35 mmHg
Visual field mean deviation score of -3 dB or worse
Shaffer Angle Grade ≥ 3
Area of free, healthy and mobile conjunctiva in the targeted quadrant
You may not be if
Active Neovascular Glaucoma
Previous glaucoma shunt/valve in the targeted quadrant
History of corneal surgery, opacities or disease/pathology
